A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak
Sign Up to like & getrecommendations! Published in 2022 at "Viruses"
DOI: 10.3390/v14091870
Abstract: Monkeypox disease (MPX) is currently considered a global threat after COVID-19. European Medicines Agency (EMA) approved Tecovirimat in capsule dosage form (200 mg) as the first treatment for MPX in January 2022. This article highlights… read more here.
Keywords: drug; patent literature; development patent; tecovirimat ... See more keywords